N-(4-(2-methoxyethoxy)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: N-(4-(2-methoxyethoxy)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine
• 英文别名: N-[4-(2-methoxyethoxy)phenyl]-5H-pyrrolo[3,2-d]pyrimidin-2-amine
• 化学式: C₁₅H₁₆N₄O₂
• 分子量: 284.318
• InChiKey: OQCLSJIKNAUALQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  72.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PHARMACYCLICS INC

  公开号：WO2014130693A1

  公开（公告）日：2014-08-28

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了与Bruton酪氨酸激酶（Btk）形成共价键的化合物。还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异免疫疾病或症状、包括淋巴瘤在内的癌症，以及炎症性疾病或症状。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：PHARMACYCLICS, LLC.

  公开号：US20160002241A1

  公开（公告）日：2016-01-07

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了能够与布鲁顿酪氨酸激酶(Btk)形成共价键的化合物。同时，还描述了Btk的不可逆抑制剂。此外，还描述了可逆抑制Btk的药物。本文还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合使用，用于治疗自身免疫性疾病或病况、异体免疫性疾病或病况、癌症，包括淋巴瘤和炎症性疾病或病况。
• US9708326B2
  申请人：——

  公开号：US9708326B2

  公开（公告）日：2017-07-18